BRIEF: InnoCare revenue jumps 37% in 2024 on strong lymphoma drug sales

9969.HK 688428.SHG
Legend is a health company

InnoCare Pharma Ltd. (9969.HK; 688428.SH) said on Thursday its revenue rose 37% last year to 1.01 billion yuan ($138 million), fueled by strong gains for Orelabrutinib, its drug used to treat lymphoma and autoimmune diseases. About 1 billion yuan of its revenue for the year came from Orelabrutinib, whose sales rose 49% year-on-year, the company said.

InnoCare continues to lose money, reporting a 443 million yuan loss for all of last year. But that figure was about 30% narrower than the 644 million yuan loss it reported in 2023. The company said its narrowing loss owed both to higher sales of Orelabrutinib, as well as improved operating efficiency as it gained greater scale.

InnoCare’s Hong Kong-listed stock rose 4% on Friday morning in Hong Kong to close at HK$5.46 by the midday break.

By Doug Young

To subscribe to Bamboo Works weekly free newsletter, click here

,
, , ,

Related Articles

RELATED ARTICLES

  1. Domino's is operated by DPC Dash in China
    DPC Dash serves up banner 2024 topped with milestones
    1405.HK
  2. Horizon’s lead grows in smart driving race with new product rollouts
    9660.HK
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva

Recent Articles

Illustration of Chinese government pumping confidence into stock market

China’s state-driven stocks, and its corporate wars abroad

China's stock market rally is fast approaching its one-year mark, with the benchmark Hang Seng and Shanghai composite indexes both up around 40%. How much longer can it last, especially given the weak state of China's economy? And internet giants Meituan and DiDi have sued each other in Brazil, where they are competing in the takeout dining market. How is this case likely to end up?
3690.HK